Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Key facts
- Who runs it
- Neurocrine Switzerland GmbH
- Where
- Ann Arbor, Atlanta, Aurora, Chicago, Dallas, Hartford, Indianapolis, Minneapolis, Philadelphia, San Francisco, and Seattle, United StatesSee the 11 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 1 Jul 2026
- Expected to end
- Mar 2028
- Type of study
- Interventional
- Treatments tested
- Crinecerfont
- Record updated
- 16 September 2026
Who can take part
- Age
- 3 months to 47 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency (21-OHD)
- Have received at least 3 months of hydrocortisone treatment before Day 1, with a stable dose for at least 4 weeks before screening
- Have a body weight of at least 4.5 kilograms (kg) at screening
- Have a newborn screen that is otherwise normal except for elevated 17-OHP or any other abnormality on newborn screen that was cleared upon evaluation by a pediatric specialist
Who cannot take part
- Have any condition besides CAH that requires chronic daily therapy with orally administered steroids
- Have any other clinically significant medical condition or chronic disease; Note: Other protocol-defined inclusion and exclusion criteria may apply
- Have a known or suspected diagnosis of any of the other forms of classic CAH
Where in United States
- Ann Arbor, MichiganHospital not named in the registryTaking people
- Atlanta, GeorgiaHospital not named in the registryTaking people
- Aurora, ColoradoHospital not named in the registryTaking people
- Chicago, IllinoisHospital not named in the registryTaking people
- Dallas, TexasHospital not named in the registryTaking people
- Hartford, ConnecticutHospital not named in the registryTaking people
- Indianapolis, IndianaHospital not named in the registryTaking people
- Minneapolis, MinnesotaHospital not named in the registryTaking people
- Philadelphia, PennsylvaniaHospital not named in the registryTaking people
- San Francisco, CaliforniaHospital not named in the registryTaking people
- Seattle, WashingtonHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to <4 years of age with CAH.
The group in the trial
- CrinecerfontTreatment being tested
Participants with CAH will receive crinecerfont.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
- Record updated
- 16 September 2026